GM Advisory Group LLC Has $350,000 Stake in Zoetis Inc. (NYSE:ZTS)

GM Advisory Group LLC boosted its stake in Zoetis Inc. (NYSE:ZTS) by 13.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,149 shares of the company’s stock after acquiring an additional 250 shares during the quarter. GM Advisory Group LLC’s holdings in Zoetis were worth $350,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ZTS. Callahan Advisors LLC lifted its holdings in shares of Zoetis by 90.4% in the fourth quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock valued at $2,135,000 after purchasing an additional 6,221 shares in the last quarter. CIBC Asset Management Inc raised its position in Zoetis by 24.1% in the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock valued at $38,617,000 after buying an additional 46,050 shares during the last quarter. Pensionfund Sabic lifted its stake in Zoetis by 55.6% in the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after acquiring an additional 4,000 shares in the last quarter. PFW Advisors LLC acquired a new position in Zoetis during the 4th quarter worth approximately $1,764,000. Finally, Alberta Investment Management Corp boosted its position in Zoetis by 2,050.0% during the 4th quarter. Alberta Investment Management Corp now owns 30,100 shares of the company’s stock worth $4,904,000 after acquiring an additional 28,700 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the sale, the executive vice president now directly owns 16,107 shares in the company, valued at $2,757,196.26. The trade was a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,862 shares of company stock worth $312,254. Insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on ZTS shares. Morgan Stanley cut their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Piper Sandler increased their price objective on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. Stifel Nicolaus lowered their target price on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Barclays boosted their price target on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. One research analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Zoetis presently has a consensus rating of “Buy” and a consensus price target of $215.90.

Zoetis Stock Performance

ZTS opened at $163.76 on Thursday. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.33. The business has a 50 day moving average of $166.81 and a 200-day moving average of $175.75. The stock has a market cap of $73.33 billion, a price-to-earnings ratio of 29.94, a PEG ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion during the quarter, compared to the consensus estimate of $2.30 billion. On average, equities research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.22%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s payout ratio is 36.56%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.